Cyclohexane is an organic compound with a chemical formula C6H12. It is a colorless liquid with a pungent odor, insoluble in water, and soluble in most organic solvents such as ethanol, ether, benzene, and acetone. Cyclohexyl fragments are a common structure in both natural and synthetic drugs. It can be used as both core structure and part of achiral side chain.
vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.